Hierarchical cluster analysis of immunophenotype classify AML patients with NPM1 gene mutation into two groups with distinct prognosis

[1]  M. Yao,et al.  Hierarchical cluster analysis of immunophenotype classify AML patients with NPM1 gene mutation into two groups with distinct prognosis , 2013, BMC Cancer.

[2]  R. Hills,et al.  The prognostic significance of IDH2 mutations in AML depends on the location of the mutation. , 2011, Blood.

[3]  J. Licht,et al.  DNMT3A mutations in acute myeloid leukemia , 2011, Nature Genetics.

[4]  J. Esteve,et al.  Immunophenotype of acute myeloid leukemia with NPM mutations: prognostic impact of the leukemic compartment size. , 2011, Leukemia research.

[5]  Chieh-Yu Liu,et al.  WT1 mutation in 470 adult patients with acute myeloid leukemia: stability during disease evolution and implication of its incorporation into a survival scoring system. , 2010, Blood.

[6]  Paola Fazi,et al.  Multilineage dysplasia has no impact on biologic, clinicopathologic, and prognostic features of AML with mutated nucleophosmin (NPM1). , 2010, Blood.

[7]  Chieh-Yu Liu,et al.  AML1/RUNX1 mutations in 470 adult patients with de novo acute myeloid leukemia: prognostic implication and interaction with other gene alterations. , 2009, Blood.

[8]  A. Kohlmann,et al.  AML with mutated NPM1 carrying a normal or aberrant karyotype show overlapping biologic, pathologic, immunophenotypic, and prognostic features. , 2009, Blood.

[9]  Ken Chen,et al.  Recurring mutations found by sequencing an acute myeloid leukemia genome. , 2009, The New England journal of medicine.

[10]  Brunangelo Falini,et al.  Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): biologic and clinical features. , 2007, Blood.

[11]  W. Finn,et al.  Unsupervised immunophenotypic profiling of chronic lymphocytic leukemia , 2006, Cytometry. Part B, Clinical cytometry.

[12]  M. Yao,et al.  Nucleophosmin mutations in de novo acute myeloid leukemia: the age-dependent incidences and the stability during disease evolution. , 2006, Cancer research.

[13]  J. Szer,et al.  The immunophenotype of acute myeloid leukemia: is there a relationship with prognosis? , 2006, Blood reviews.

[14]  Natalia Meani,et al.  Acute myeloid leukemia bearing cytoplasmic nucleophosmin (NPMc+ AML) shows a distinct gene expression profile characterized by up-regulation of genes involved in stem-cell maintenance. , 2005, Blood.

[15]  R. Campanini,et al.  Signature of B‐CLL with different prognosis by Shrunken centroids of surface antigen expression profiling , 2005, Journal of cellular physiology.

[16]  Jih-Luh Tang,et al.  Characterization of CEBPA Mutations in Acute Myeloid Leukemia: Most Patients with CEBPA Mutations Have Biallelic Mutations and Show a Distinct Immunophenotype of the Leukemic Cells , 2005, Clinical Cancer Research.

[17]  Paola Fazi,et al.  Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. , 2005, The New England journal of medicine.

[18]  D. Campana.  Minimal residual disease studies in acute leukemia. , 2004, American journal of clinical pathology.

[19]  M. Yao,et al.  Chromosomal abnormalities of 200 Chinese patients with non-Hodgkin's lymphoma in Taiwan: with special reference to T-cell lymphoma. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[20]  S. Bicciato,et al.  Acute Leukemia Subclassification: A Marker Protein Expression Perspective , 2004, Hematology.

[21]  W. Ludwig,et al.  The prognostic significance of antigen expression in leukaemia. , 2003, Best practice & research. Clinical haematology.

[22]  D. Campana,et al.  Minimal residual disease monitoring by flow cytometry. , 2003, Best practice & research. Clinical haematology.

[23]  X Thomas,et al.  Prognostic significance of FLT3 internal tandem repeat in patients with de novo acute myeloid leukemia treated with reinforced courses of chemotherapy , 2002, Leukemia.

[24]  O. Hrusak,et al.  Antigen expression patterns reflecting genotype of acute leukemias , 2002, Leukemia.

[25]  M. Borowitz,et al.  Flow cytometry in the diagnosis of acute leukemia. , 2001, Seminars in hematology.

[26]  N. Casadevall,et al.  The immunophenotype of 177 adults with acute myeloid leukemia: proposal of a prognostic score. , 2000, Blood.

[27]  R. R. Schreck,et al.  ISCN Standard Idiograms , 1998, Current protocols in human genetics.

[28]  Y C Chen,et al.  Correlation of cytogenetic results with immunophenotype, genotype, clinical features, and ras mutation in acute myeloid leukemia. A study of 235 Chinese patients in Taiwan. , 1995, Cancer genetics and cytogenetics.

[29]  J. Matthews,et al.  Prognostic value of immunophenotyping in acute myeloid leukemia. Australian Leukaemia Study Group. , 1994, Blood.

[30]  E. Solary,et al.  Surface markers in adult acute myeloblastic leukemia: correlation of CD19+, CD34+ and CD14+/DR--phenotypes with shorter survival. Groupe d'Etude Immunologique des Leucémies (GEIL). , 1992, Leukemia.

[31]  J. Matthews,et al.  Australian Leukaemia Study Group Prognostic value of immunophenotyping in acute myeloid leukemia. , 2011 .

[32]  T. Haferlach,et al.  Monitoring of minimal residual disease in acute myeloid leukemia , 2008, Cancer.

[33]  M. Minden,et al.  Prognostic relevance of immunophenotyping in 379 patients with acute myeloid leukemia. , 2004, Leukemia research.

[34]  R. Foà,et al.  Immunophenotypic analysis in 119 patients with acute myeloid leukemia following a previous malignancy: a comparison with the immunophenotype of 231 de novo AML. , 2003, Haematologica.

[35]  D. Birnbaum,et al.  BMC Cancer , 2003 .

[36]  M. Yao,et al.  Clinical and biological implications of partial tandem duplication of the MLL gene in acute myeloid leukemia without chromosomal abnormalities at 11q23 , 2002, Leukemia.

[37]  T. Lister,et al.  Immunophenotype of blast cells in acute myeloid leukemia may be a useful predictive factor for outcome , 1990, Hematological oncology.